MedPath

Otsuka Beijing Research Institute

Otsuka Beijing Research Institute logo
🇨🇳China
Ownership
Subsidiary
Established
2003-08-29
Employees
-
Market Cap
-
Website
http://www.obri.com.cn

Clinical Trials

36

Active:2
Completed:33

Trial Phases

5 Phases

Phase 1:10
Phase 2:5
Phase 3:12
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials

Phase 3
12 (33.3%)
Phase 1
10 (27.8%)
Not Applicable
5 (13.9%)
Phase 2
5 (13.9%)
Phase 4
4 (11.1%)

a Phase I PK Study in Healthy Male Subjects. 2 Groups of Healthy Male Subjects

Not Applicable
Completed
Conditions
Health Subjects
Interventions
Drug: singe dose 15mg
Drug: multi dose 30mg
Drug: single dose 30mg
Drug: multi dose 60mg
Drug: single dose 60mg
Drug: single dose 120mg
First Posted Date
2025-09-10
Last Posted Date
2025-09-10
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
64
Registration Number
NCT07166796

Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol

Not Applicable
Completed
Conditions
Health Subjects
Interventions
First Posted Date
2025-09-10
Last Posted Date
2025-09-10
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
10
Registration Number
NCT07166783

Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male

Not Applicable
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2025-09-10
Last Posted Date
2025-09-10
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
12
Registration Number
NCT07166887

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Not Applicable
Completed
Conditions
Healthy Subjects (HS)
Interventions
First Posted Date
2025-08-05
Last Posted Date
2025-08-05
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
24
Registration Number
NCT07105124
Locations
🇨🇳

West China Hospital of Sichuan University, Chengdu, Sichuan, China

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Phase 1
Active, not recruiting
Conditions
Myelodysplastic Syndromes
Interventions
First Posted Date
2023-10-19
Last Posted Date
2025-06-26
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
72
Registration Number
NCT06091267
Locations
🇨🇳

The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.